Sweden · Delayed Price · Currency is SEK Vitrolife AB Statistics
Total Valuation
Vitrolife AB has a market cap or net worth of SEK 19.95 billion. The enterprise value is 20.84 billion.
| Market Cap | 19.95B |
| Enterprise Value | 20.84B |
Important Dates
The next estimated earnings date is Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Apr 30, 2025 |
Share Statistics
Vitrolife AB has 135.42 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 135.42M |
| Shares Outstanding | 135.42M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 64.50% |
| Float | 75.04M |
Valuation Ratios
The trailing PE ratio is 45.34 and the forward PE ratio is 33.88. Vitrolife AB's PEG ratio is 3.02.
| PE Ratio | 45.34 |
| Forward PE | 33.88 |
| PS Ratio | 5.69 |
| PB Ratio | 1.50 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 34.51 |
| P/OCF Ratio | 26.88 |
| PEG Ratio | 3.02 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.30, with an EV/FCF ratio of 36.06.
| EV / Earnings | 47.37 |
| EV / Sales | 5.94 |
| EV / EBITDA | 19.30 |
| EV / EBIT | 31.44 |
| EV / FCF | 36.06 |
Financial Position
The company has a current ratio of 4.40, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.40 |
| Quick Ratio | 3.47 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 1.85 |
| Debt / FCF | 3.46 |
| Interest Coverage | 11.43 |
Financial Efficiency
Return on equity (ROE) is 3.34% and return on invested capital (ROIC) is 2.72%.
| Return on Equity (ROE) | 3.34% |
| Return on Assets (ROA) | 2.46% |
| Return on Invested Capital (ROIC) | 2.72% |
| Return on Capital Employed (ROCE) | 4.06% |
| Revenue Per Employee | 3.19M |
| Profits Per Employee | 400,000 |
| Employee Count | 1,169 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 3.47 |
Taxes
In the past 12 months, Vitrolife AB has paid 146.00 million in taxes.
| Income Tax | 146.00M |
| Effective Tax Rate | 24.87% |
Stock Price Statistics
The stock price has decreased by -39.08% in the last 52 weeks. The beta is 1.77, so Vitrolife AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | -39.08% |
| 50-Day Moving Average | 137.64 |
| 200-Day Moving Average | 157.32 |
| Relative Strength Index (RSI) | 58.65 |
| Average Volume (20 Days) | 95,231 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vitrolife AB had revenue of SEK 3.51 billion and earned 440.00 million in profits. Earnings per share was 3.25.
| Revenue | 3.51B |
| Gross Profit | 2.07B |
| Operating Income | 663.00M |
| Pretax Income | 587.00M |
| Net Income | 440.00M |
| EBITDA | 1.03B |
| EBIT | 663.00M |
| Earnings Per Share (EPS) | 3.25 |
Balance Sheet
The company has 1.11 billion in cash and 2.00 billion in debt, giving a net cash position of -893.00 million or -6.59 per share.
| Cash & Cash Equivalents | 1.11B |
| Total Debt | 2.00B |
| Net Cash | -893.00M |
| Net Cash Per Share | -6.59 |
| Equity (Book Value) | 13.30B |
| Book Value Per Share | 98.21 |
| Working Capital | 1.79B |
Cash Flow
In the last 12 months, operating cash flow was 742.00 million and capital expenditures -164.00 million, giving a free cash flow of 578.00 million.
| Operating Cash Flow | 742.00M |
| Capital Expenditures | -164.00M |
| Free Cash Flow | 578.00M |
| FCF Per Share | 4.27 |
Margins
Gross margin is 58.91%, with operating and profit margins of 18.91% and 12.55%.
| Gross Margin | 58.91% |
| Operating Margin | 18.91% |
| Pretax Margin | 16.74% |
| Profit Margin | 12.55% |
| EBITDA Margin | 29.40% |
| EBIT Margin | 18.91% |
| FCF Margin | 16.48% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 0.75%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 0.75% |
| Dividend Growth (YoY) | 10.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 33.86% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 0.68% |
| Earnings Yield | 2.21% |
| FCF Yield | 2.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 17, 2018. It was a forward split with a ratio of 5.
| Last Split Date | May 17, 2018 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Vitrolife AB has an Altman Z-Score of 4.43 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.43 |
| Piotroski F-Score | 7 |